GSK has set its sights on dominance of the market for hepatitis B virus (HBV) therapeutics, licensing an antisense oligonucleotide drug from Arrowhead Pharma and Johnson &
GSK has revealed updated results from its phase 2b trial of its antisense drug for hepatitis B virus (HBV) infections, which reveal a sharp decline in the proportion of patients with undete
In this episode of the pharmaphorum podcast series, Dr Paul Tunnah chats with Jeff Baxter, CEO of VBI Vaccines and Lee Taurman, executive vice president full service commercial at Syneos Health.
Johnson & Johnson has halved the size of its collaboration with Bavarian Nordic on vaccine development, jettisoning its stake in shots targeting human papillomavirus (HPV) and hepatitis
The US FDA announced today that it has cleared two novel gene therapies for sickle cell disease: Vertex Pharmaceuticals' Casgevy and bluebird bio's Lyfgenia.
On 1st October, the roll-out of the National Contract Value Review (NCVR) process marked a pivotal moment in the trajectory of clinical research in the UK, introducing a standardised, natio